Publications by authors named "A Khera"
Novel Therapeutic Agents for Cardiometabolic Risk Mitigation in Heart Transplant Recipients.
J Heart Lung Transplant
December 2024
Heart transplant (HT) recipients experience high rates of cardiometabolic disease. Novel therapies targeting hyperlipidemia, diabetes, and obesity, including proprotein convertase subtilisin/kexin inhibitors (PCSK9i), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists are increasingly used for cardiometabolic risk mitigation in the general population. However, limited data exist to support the use of these agents in patients who have undergone heart transplantation.
View Article and Find Full Text PDFSocial media, integral to contemporary life, offers significant connectivity and entertainment benefits. However, its pervasive use has given rise to social media addiction, particularly among teenagers, characterized by excessive screen time, compulsive checking, and detrimental effects on real-life relationships and responsibilities. This addiction is driven by a combination of psychological factors, such as low self-esteem and mental health issues, technological mechanisms like infinite scrolling and personalized notifications, and social influences, including peer pressure and exposure to idealized content.
View Article and Find Full Text PDFArticle Synopsis
- Polygenic risk scores (PRSs) could enhance disease risk prediction, but their current effectiveness is compromised for non-European populations, creating potential health disparities.
- The PRIMED Consortium aims to improve PRS performance by aggregating diverse genetic data on a cloud platform and evaluating ethical implications related to its implementation.
- Focused on cardiometabolic diseases and cancer, PRIMED seeks to promote equity in polygenic risk assessment through collaboration across multiple research sites and organizations.
Precision medicine aims to provide personalized clinical care guided by tools that reflect underlying pathophysiology. The need for such an approach has never been greater in cardiovascular medicine, given the large number of guideline-directed medical therapies available. However, progress has been modest to date with few precision tools available for clinicians.
View Article and Find Full Text PDFPolygenic risk, aspirin and primary prevention of coronary artery disease.
Eur Heart J Cardiovasc Pharmacother
October 2024
Article Synopsis
- Recent trials show that aspirin for preventing heart disease often leads to more bleeding risks than benefits, particularly in the general population.
- This study analyzed data from the ASPREE trial, focusing on individuals with a high genetic risk for coronary artery disease (CAD).
- Findings revealed that those in the highest genetic risk group experienced a significant reduction in CAD events with aspirin, without increased bleeding risk, suggesting aspirin may be beneficial for high-risk individuals.